For UK Healthcare Professionals Only
Adverse events should be reported. Reporting forms and information can be found at: yellowcard.mhra.gov.uk
Adverse events should also be reported to Aspire Pharma Ltd on +44 (0)1730 231148.

For more information about products within the Pathway Portfolio, please click here for prescribing information

Pain

The Pathway Portfolio is Aspire Pharma’s branded generic portfolio with products covering a wide range of therapy areas, including: CNS, Respiratory, Cardiovascular, Pain and Urology.

Each product in the portfolio has its own key offerings, ranging from:

  • A full range of strengths available1
  • A first strength to market1
  • Simpler dosing which may help some patients with concordance and compliance1-2
  • The first brand to market1

All of which create a wider offering to patients.

Pathway to Partnership:

Trusted Brands:

  • Bioequivalent to brand originators3
  • Available from mainline wholesalers

Bespoke Support:

  • Price guarantee
  • Individualised rebates on request
Contact a member of our team

Please click here for Sevodyne® prescribing information

Sevodyne® (buprenorphine) transdermal patches

Indicated for the treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia4.

  • Available as 5, 10, 15 and 20µg/hr4

  • All 4 strengths bioequivalent to the originator brand3

CONTACT US TO REQUEST
A COST SAVING REPORT

69% savings across all 4 strengths on the UK Drug Tariffs1.

Sevodyne® could reduce the average ICS/ICB prescribing costs of buprenorphine transdermal patches by an average of £134,822 per annum, saving up to £4,853,594 annually across the NHS5*.

Please click on the buttons to download Sevodyne patient materials. If you would like to order printed versions of any of the materials listed, please click here to contact one of our representatives.

Patient guide for applying the 7-day patch Patient patch application record card

References:

*Average ICS is based on 4 x Moving Quarterly Turnover (MQT) divided by 42 ICS/ICB’s

  1. UK Drug Tariff (Accessed June 2026)
  2. Kyoko Higashiet al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 2013; 9: 119–131 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552550/
  3. REF-00061-1 | Bioequivalence Data on File
  4. Sevodyne® SmPC (Accessed June 2026)
  5. MAT-UK-EPI-0139-1 Pathway Portfolio cost savings, GPPLPD Date Range: Jan-26 – Mar-26

MAT-UK-XLP-0035-1 | June 2026